Search results
If You Invested $1000 in AbbVie a Decade Ago, This is How Much It'd Be Worth Now
Zacks via Yahoo Finance· 10 hours agoThe company also has partnerships with companies like Roche...
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 7 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 6 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Amgen Inc. (NASDAQ:AMGN) Stake Lowered by First PREMIER Bank
ETF DAILY NEWS· 7 hours agoFirst PREMIER Bank reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.1% during the 1st quarter, according to the company in its most recent filing with the Securities ...
NBC Securities Inc. Has $1.77 Million Stake in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 5 days agoNBC Securities Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.0% in the 1st quarter, according to the company in its most recent filing with the Securities ...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 3 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 5 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 4 days agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis,
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 4 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...